News Headlines Article

With FDA approval, Berkeley’s got a brand new drug
San Francisco Business Times

A next-generation blood-clotting treatment — made and tested at Bayer HealthCare’s Berkeley campus — won approval from the Food and Drug Administration for use by hemophilia A patients, the company said Thursday. FDA approval of Kovaltry, which last month scored European and Canadian regulatory approvals, is a next-step move by Bayer to protect and build on its longtime hemophilia A franchise. Kogenate FS for hemophilia A patients is the German company’s second-best-selling product, and Bayer continues development of an experimental once-a-week treatment, called damoctocog.